M1 macrophage-related gene model for NSCLC immunotherapy response prediction

Patients diagnosed with non-small cell lung cancer (NSCLC) have a limited lifespan and exhibit poor immunotherapy outcomes. M1 macrophages have been found to be essential for antitumor immunity. This study aims to develop an immunotherapy response evaluation model for NSCLC patients based on transcr...

Full description

Saved in:

Bibliographic Details
Published in:	Acta biochimica et biophysica Sinica Vol. 56; no. 3; pp. 379 - 392
Main Authors:	Wu, Sifan, Sheng, Qiqi, Liu, Pengjun, Jiao, Zhe, Lv, Jinru, Qiao, Rong, Xie, Dongkun, Wang, Zanhan, Ge, Jiamei, Li, Penghui, Wei, Tiaoxia, Lei, Jie, Fan, Jieyi, Wang, Liang
Format:	Journal Article
Language:	English
Published:	China Science Press 21-02-2024 China Science Publishing & Media Ltd
Subjects:	Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - therapy Humans immune infiltration Immunotherapy Lung Neoplasms - genetics Lung Neoplasms - therapy M1 macrophage Macrophages NSCLC Populus prognosis prediction model Tumor Microenvironment prognosis prediction model NSCLC immune infiltration M1 macrophage immunotherapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Patients diagnosed with non-small cell lung cancer (NSCLC) have a limited lifespan and exhibit poor immunotherapy outcomes. M1 macrophages have been found to be essential for antitumor immunity. This study aims to develop an immunotherapy response evaluation model for NSCLC patients based on transcription. RNA sequencing profiles of 254 advanced-stage NSCLC patients treated with immunotherapy are downloaded from the POPLAR and OAK projects. Immune cell infiltration in NSCLC patients is examined, and thereafter, different coexpressed genes are identified. Next, the impact of M1 macrophage-related genes on the prognosis of NSCLC patients is investigated. Six M1 macrophage coexpressed genes, namely, , , , , , and , exhibit a strong association with the prognosis of NSCLC and serve as effective predictors for immunotherapy response. A response model is constructed using a Cox regression model and Lasso Cox regression analysis. The M1 genes are validated in our TD-FOREKNOW NSCLC clinical trial by RT-qPCR. The response model shows excellent immunotherapy response prediction and prognosis evaluation value in advanced-stage NSCLC. This model can effectively predict advanced NSCLC prognosis and aid in identifying patients who could benefit from customized immunotherapy as well as sensitive drugs.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work.
ISSN:	1672-9145 1745-7270
DOI:	10.3724/abbs.2023262